Rigel Mulls Next Steps After Fostamatinib Fails In Kidney Disease
Executive Summary
Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.